NEJM June 2026 Phase 3 Results of Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection.

This clinical report evaluates the efficacy of bepirovirsen, an innovative antisense oligonucleotide designed to achieve a functional cure for chronic hepatitis B by suppressing viral markers for an extended period. Through two large-scale phase 3 trials, researchers demonstrated that a fixed-duration regimen significantly outperformed a placebo in clearing the virus and allowing patients to safely discontinue traditional therapies. While the drug proved successful in roughly one-fifth of participants, the study also notes a higher frequency of adverse events, particularly liver enzyme elevations, compared to the control group. Ultimately, the text highlights a major medical advancement by proving that this targeted genetic intervention can lead to sustained viral remission in a meaningful portion of the patient population.